Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.

• To evaluate docetaxel or vinorelbine, both with trastuzumab, as first-line therapy of human epidermal growth factor receptor 2-positive advanced breast cancer.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Adult

Aged

Antibodies

Monoclonal

administration & dosage

adverse effects

Antineoplastic Combined Chemotherapy Protocols

adverse effects

therapeutic use

Breast Neoplasms

drug therapy

Female

Humans

Middle Aged

Multivariate Analysis

Proportional Hazards Models

Receptor

erbB-2

antagonists & inhibitors

metabolism

Survival Analysis

Taxoids

administration & dosage

adverse effects

Vinblastine

administration & dosage

adverse effects

analogs & derivatives

Publication and Content Type

ref (subject category)

for (subject category)